Northern Trust’s Lucid Diagnostics LUCD Stock Holding History

Northern Trust’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Buy	1,219,879 +549,294	+82%	+$592K	﹤0.01%	3363
2026 Q1	$771K	Buy	670,585 +33,571	+5%	+$42.7K	﹤0.01%	3448
2025 Q4	$694K	Buy	637,014 +133,269	+26%	+$149K	﹤0.01%	3535
2025 Q3	$509K	Sell	503,745 -25,674	-5%	-$28K	﹤0.01%	3636
2025 Q2	$609K	Buy	529,419 +487,639	+1,167%	+$630K	﹤0.01%	3592
2025 Q1	$62.3K	Buy	41,780 +28,652	+218%	+$34.4K	﹤0.01%	4197
2024 Q4	$10.7K	Hold	13,128	–	–	﹤0.01%	4420
2024 Q3	$10.7K	Hold	13,128	–	–	﹤0.01%	4376
2024 Q2	$10.8K	Sell	13,128 -17	-0.1%	-$14	﹤0.01%	4375
2024 Q1	$10.6K	Buy	+13,145	New	+$17.1K	﹤0.01%	4385
2022 Q2	–	Sell	-40,834	Closed	-$137K	–	4787
2022 Q1	$137K	Buy	40,834 +2,182	+6%	+$7.97K	﹤0.01%	4255
2021 Q4	$207K	Buy	+38,652	New	+$314K	﹤0.01%	4184

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Northern Trust's LUCD Position: Q2 2026 in Review

Northern Trust increased its Lucid Diagnostics (LUCD) stake by 82% in Q2 2026, buying an estimated $592K and bringing the position to 1,219,879 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3363.

Northern Trust first reported a position in LUCD in Q4 2021 and has held it in 12 quarters since. 115 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Northern Trust held 1,219,879 shares of Lucid Diagnostics worth $1.31M as of Q2 2026.
Northern Trust bought 549,294 Lucid Diagnostics shares in Q2 2026, an estimated $592K.
Lucid Diagnostics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3363 holding.
Northern Trust first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 12 quarters since.
115 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.